Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA XIST decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 12/January/2018, 8.11 am
January 12, 2019
Ribonucleic acid-based therapy for diabetes: LncRNA PVT1-214 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 12/January/2019, 8.37 am
January 12, 2019
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journalNature Medicine[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests provide mechanistic insights into how the anti-hyperglycemic drug Pioglitazone may attenuate pulmonary arterial hypertension.

Pioglitazoneby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, Pioglitazone  or its analogs, either alone or in combination with other drugs,”may be used to treat pulmonary arterial hypertension (Fig. 2). 

Figure 1. Mechanistic insights into how pioglitazone may function as an anti-pulmonary arterial hypertensive agent.  Pioglitazone may promote insulin sensitivity and protect against myocardial infarction, via up-regulation of reprogramming protein Lin-28

Figure 2.  pioglitazone may inhibit pulmonary arterial hypertension through down-regulation of Notch-3 and its target gene Hes5

 


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How  pioglitazone decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Repurposing the anti-hyperglycemic drug Pioglitazone into an anti-pulmonary arterial hypertension drug: Pioglitazone (brand name: Actos) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 12/January/2019, 8.23 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.